



## (51) International Patent Classification:

*C07D 487/04* (2006.01) *A61P 35/00* (2006.01)  
*A61K 31/519* (2006.01) *A61P 37/00* (2006.01)  
*A61P 29/00* (2006.01)

## (21) International Application Number:

PCT/IB2015/053975

## (22) International Filing Date:

27 May 2015 (27.05.2015)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

14170408.0 28 May 2014 (28.05.2014) EP

## (71) Applicant (for all designated States except US): NO-VARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

## (72) Inventors; and

(71) Applicants (for US only): **PISSOT SOLDERMANN, Carole** [FR/CH]; Novartis Pharma AG, Novartis Institutes for Biomed. Research, Postfach, CH-4002 Basel (CH). **QUANCARD, Jean** [FR/CH]; Novartis Pharma AG, Novartis Institutes for Biomed. Research, Postfach, CH-4002 Basel (CH). **SCHLAPBACH, Achim** [DE/CH]; Novartis Pharma AG, Novartis Institutes for Biomed. Research, Postfach, CH-4002 Basel (CH). **SIMIC, Oliver** [DE/CH]; Novartis Pharma AG, Novartis Institutes for Biomed. Research, Postfach, CH-4002 Basel (CH). **TINTEL-NOT-BLOMLEY, Marina** [DE/CH]; Novartis Pharma AG, Novartis Institutes for Biomed. Research, Postfach,

CH-4002 Basel (CH). **ZOLLER, Thomas** [DE/CH]; Novartis Pharma AG, Novartis Institutes for Biomed. Research, Postfach, CH-4002 Basel (CH).

## (74) Common Representative: NOVARTIS AG; Lichtstrasse 35, CH-4056 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RA, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

## Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

[Continued on next page]

## (54) Title: NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES AND THEIR USE AS MALT1 INHIBITORS



(I)

(57) Abstract: The present invention describes new pyrazolo-pyrimidine derivatives of formula (I) or a pharmaceutically acceptable salt thereof; (I) wherein, R1 is halogen, cyano, or C<sub>1</sub>-C<sub>3</sub>alkyl optionally substituted by halogen; R2 is C<sub>1</sub>-C<sub>6</sub>alkyl optionally substituted one or more times by C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl, hydroxyl, N,N-di-C<sub>1</sub>-C<sub>6</sub>alkyl amino, N-mono-C<sub>1</sub>-C<sub>6</sub>alkyl amino, O-Rg, Rg, phenyl, or by C<sub>1</sub>-C<sub>6</sub>alkoxy wherein said alkoxy again may optionally be substituted by C<sub>1</sub>-C<sub>6</sub>alkoxy, N,N-di-C<sub>1</sub>-C<sub>6</sub>alkyl amino, Rg or phenyl; C<sub>3</sub>-C<sub>6</sub>cycloalkyl optionally substituted by C<sub>1</sub>-C<sub>6</sub>alkyl, N,N-di-C<sub>1</sub>-C<sub>6</sub>alkyl amino or C<sub>1</sub>-C<sub>6</sub>alkoxy-C<sub>1</sub>-C<sub>6</sub>alkyl, and/or two of said optional substituents together with the atoms to which they are bound may form an annulated or spirocyclic 4 - 6 membered saturated heterocyclic ring comprising 1 - 2 O atoms; phenyl optionally substituted by C<sub>1</sub>-C<sub>6</sub>alkoxy; a 5 - 6 membered heteroaryl ring having 1 to 3 heteroatoms selected from N and O said ring being optionally substituted by C<sub>1</sub>-C<sub>6</sub>alkyl which may be optionally substituted by amino or hydroxy; Rg; or N,N-di-C<sub>1</sub>-C<sub>6</sub>alkyl amino carbonyl; and R is phenyl independently substituted two or more times by Ra, 2-pyridyl independently substituted one or more times by Rb, 3-pyridyl independently substituted one or more times by Rc, or 4-pyridyl independently substituted one or more times by Rd; which are generally interacting with MALT1 proteolytic and/or autoprolytic activity, and in particular which may inhibit said activity. The present invention further describes the synthesis of said new pyrazolo-pyrimidine derivatives, their use as a medicament, especially by interacting with MALT1 proteolytic and/or autoprolytic activity.

**WO 2015/181747 A1**



---

**Published:**

— *with international search report (Art. 21(3))*